Radius Health, Inc. (RDUS) Position Maintained by Great West Life Assurance Co. Can

Great West Life Assurance Co. Can held its position in Radius Health, Inc. (NASDAQ:RDUS) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,200 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Great West Life Assurance Co. Can’s holdings in Radius Health were worth $145,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of RDUS. BlackRock Inc. grew its position in shares of Radius Health by 98,245.6% during the 1st quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after acquiring an additional 2,628,070 shares during the period. Credit Agricole S A acquired a new stake in shares of Radius Health during the 1st quarter valued at about $10,026,000. BB Biotech AG grew its position in shares of Radius Health by 4.1% during the 1st quarter. BB Biotech AG now owns 4,540,399 shares of the biopharmaceutical company’s stock valued at $175,486,000 after acquiring an additional 180,000 shares during the period. Bank of New York Mellon Corp grew its position in shares of Radius Health by 67.8% during the 1st quarter. Bank of New York Mellon Corp now owns 444,049 shares of the biopharmaceutical company’s stock valued at $17,163,000 after acquiring an additional 179,471 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Radius Health by 3.2% during the 1st quarter. Vanguard Group Inc. now owns 3,010,646 shares of the biopharmaceutical company’s stock valued at $116,362,000 after acquiring an additional 93,188 shares during the period.

Shares of Radius Health, Inc. (RDUS) opened at 33.54 on Friday. The company has a 50-day moving average price of $37.32 and a 200 day moving average price of $39.12. The firm’s market capitalization is $1.46 billion. Radius Health, Inc. has a 12-month low of $31.58 and a 12-month high of $59.22.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.23). The company had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $1.96 million. During the same period in the prior year, the company earned ($1.01) earnings per share. On average, equities analysts expect that Radius Health, Inc. will post ($5.58) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/09/17/radius-health-inc-rdus-position-maintained-by-great-west-life-assurance-co-can.html.

A number of equities research analysts have recently commented on the company. Jefferies Group LLC restated a “hold” rating and set a $38.00 target price (up from $34.00) on shares of Radius Health in a research report on Wednesday, August 9th. Zacks Investment Research upgraded Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. BidaskClub cut Radius Health from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Cantor Fitzgerald set a $58.00 target price on Radius Health and gave the company a “buy” rating in a research report on Sunday, July 23rd. Finally, Canaccord Genuity set a $85.00 target price on Radius Health and gave the company a “buy” rating in a research report on Monday, July 17th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $53.60.

In related news, insider Jesper Hoiland bought 6,100 shares of the company’s stock in a transaction on Friday, September 15th. The stock was bought at an average cost of $32.72 per share, with a total value of $199,592.00. Following the completion of the acquisition, the insider now owns 6,100 shares in the company, valued at approximately $199,592. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Growth N. V. Biotech bought 150,000 shares of the company’s stock in a transaction on Thursday, September 14th. The stock was bought at an average cost of $33.45 per share, with a total value of $5,017,500.00. Following the completion of the acquisition, the insider now owns 5,448,799 shares of the company’s stock, valued at approximately $182,262,326.55. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 469,100 shares of company stock valued at $16,328,382. 15.00% of the stock is currently owned by corporate insiders.

Radius Health Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply